Gilead Sciences has agreed to acquire Immunomedics for about $21 billion, offering it a probable blockbuster breast most cancers drug...
Exclusive
Breaking News
A Different Route to Global Market Exposure for Singapore Savers
Unlocking the Language of Numbers: Creative Strategies in Financial Accounting
Top 10 Investment Firms Ruling Global Markets in 2024